After losing its market edge to Eli Lilly (LLY 0.01%) despite its first-mover advantage in weight-loss drugs, Novo Nordisk is trying to close the gap. The maker of the semaglutide GLP-1 weight loss drug Wegovy launched a pill-based version at the start of this year. Still, much suggests that Eli Lilly could still stay on top.
Last quarter, sales of its anti-obesity drug, Zepbound were up 80% from a year ago. The upcoming launch of newer, more powerful products could further cement its dominance. This will likely drive continued strong performance for the popular pharmaceutical stock.
Image source: Getty Images.
Eli Lilly and its gambit to stay on top of the GLP-1 heap
By launching a pill-based version of Wegovy, Novo Nordisk is capitalizing on patients’ preference for oral treatments over injectables.
Today’s Change
(-0.01%) $-0.05
Current Price
$1004.92
Key Data Points
Market Cap
$946B
Day’s Range
$997.41 – $1014.38
52wk Range
$623.78 – $1133.95
Volume
2.8M
Avg Vol
3.1M
Gross Margin
82.83%
Dividend Yield
0.79%
However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has another drug candidate, retatrutide, that targets GLP-1 and GIP receptors, as well as glucagon receptors.
That’s significant given Eli Lilly’s other therapies. A key reason for the success of its Zepbound drug is its status as a “dual agonist.” Wegovy targets only GLP-1 receptors, whereas tirzepatide (aka Zebound) targets both GLP-1 and GIP receptors, leading to greater overall weight loss. With retatrutide, Eli Lilly aims to bring to market a “triple agonist,” targeting GLP-1 and GIP receptors, as well as glucagon receptors. Meanwhile, Novo Nordisk is still developing its own “dual agonist” product.
What this means for the stock
In March, Eli Lilly unveiled promising phase 3 clinical trial data for retatrutide. In this trial, the drug resulted in significant reductions in A1C and weight loss among participants.
Retatrutide remains months, if not a year, away from launch, but bullishness about its high commercial potential could help keep Eli Lilly at elevated prices. Trading for over $1,000 per share, the stock may seem pricey at over 26 times forward earnings. However, if Eli Lilly’s follow-up products help it maintain its edge, the market will continue to consider it one of the top GLP-1 stocks, enabling it to sustain a premium valuation.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.
